


RESEARCH ARTICLE

# First evaluation of the Next-Generation Sequencing platform for the detection of HIV-1 drug resistance mutations in Belgium

Géraldine Dessilly<sup>1\*</sup>, Léonie Goeminne<sup>1</sup>, Anne-thérèse Vandenbroucke<sup>1</sup>, Francois E. Dufrasne<sup>1</sup>, Anandi Martin<sup>1</sup>, Benoît Kabamba-Mukabi<sup>1,2</sup>

**1** Université catholique de Louvain (UCLouvain), Institut de Recherche Expérimentale et Clinique (IREC), Medical Microbiology Unit (MBLG), AIDS Reference Laboratory, Brussels, Belgium, **2** Université catholique de Louvain (UCLouvain), Cliniques Universitaires Saint-Luc, Clinical Laboratory Department, Brussels, Belgium

\* [geraldine.dessilly@uclouvain.be](mailto:geraldine.dessilly@uclouvain.be)



## Abstract

### Introduction

The WHO urges action against the threat posed by HIV drug resistance. It is well known that the sensitivity of Next-Generation Sequencing (NGS) is greater than that of Sanger Sequencing (SS). The objective of this study was to evaluate the performance of the novel NGS HIV-1 drug resistance monitoring system.

### Materials & methods

NGS analyses were performed on 67 plasma samples from HIV-1 infected patients using the *Sentosa* SQ HIV Genotyping Assay from Vela-Dx. This kit was used on a semi-automated Ion Torrent-based platform. Sequences were compared to those obtained by SS. Samples were analysed in the same and in separate runs. Quality controls (QC) were added to control sequencing processes of protease (PRO), reverse transcriptase (RT) and integrase (INT) regions.

### Results

Of the 41 analysed samples, 33 (80.5%) had identical drug resistance interpretation reports. Discrepant results were observed for eight samples. Five of them were only detected by NGS and had drug resistance mutations (DRMs) with an allelic frequency below the limit of detection of the SS method (between 6.3 to 20.5%). Two DRMs were only identified using the SS method. The sequences were similar in 98.2% of cases (counting variants as mismatches) and homologous in 99.9% if missed variants. Duplicated samples in a single run were similar in 95.7% (99.9%) of cases. Duplicated samples in two different runs were 98% (100%) homologous. QC results were manually assessed with a score of 340/340 for detection of DRMs in PRO and RT and 100% for INT sequencing.

## OPEN ACCESS

**Citation:** Dessilly G, Goeminne L, Vandenbroucke A-t, Dufrasne FE, Martin A, Kabamba-Mukabi B (2018) First evaluation of the Next-Generation Sequencing platform for the detection of HIV-1 drug resistance mutations in Belgium. PLoS ONE 13(12): e0209561. <https://doi.org/10.1371/journal.pone.0209561>

**Editor:** Dimitrios Paraskevis, National and Kapodistrian University of Athens, GREECE

**Received:** April 16, 2018

**Accepted:** November 12, 2018

**Published:** December 31, 2018

**Copyright:** © 2018 Dessilly et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are within the paper.

**Funding:** The authors received no specific funding for this study.

**Competing interests:** The authors have declared that no competing interests exist.

## Conclusions

This is the first preliminary evaluation in Belgium employing the *Sentosa* SQ HIV Genotyping Assay. The NGS appears to be a promising tool for the detection of DRMs in HIV-1 patients and showed a higher sensitivity compared to SS. Large studies assessing the clinical relevance of low frequency DRMs are needed.

## 1. Introduction

Human immunodeficiency virus (HIV) type 1 is the agent responsible for acquired immunodeficiency syndrome (AIDS) and for the majority of HIV infections worldwide [1, 2]. Although the number of newly diagnosed cases of HIV decreases from year to year, the number of infected patients is continuing to increase with a total of 15 000 diagnosed patients in follow-up in Belgium [3] and an estimation of 36.7 millions of people living with HIV in the worldwide [4].

The current treatment for HIV consists of a combination of antiretroviral drugs (ARV), typically three drugs from two or more classes [5]. The ARV regimen for a treatment-naïve patient generally consists of two nucleoside reverse transcriptase inhibitors (NRTIs) in combination with a third active ARV drug from one of three drug classes: an integrase strand transfer inhibitor (INSTI), a non-nucleoside reverse transcriptase inhibitor (NNRTI), or a protease inhibitor (PI) with a pharmacokinetic (PK) enhancer (booster) (cobicistat or ritonavir) [5].

Viral load is the most important indicator of initial and sustained response to ART and should be measured in all patients with HIV at entry into care, at initiation of therapy and on a regular basis thereafter. The level of viral load level before treatment is also an important factor in the selection of an initial ARV regimen because several currently approved ARV drugs have been associated with poor responses in patients with high baseline viral load. The goal of ARV treatment (ART) is to continually keep plasma HIV-RNA levels below the level of detection, 50 RNA viral copies/mL (c/mL), depending on the assay used [5]. Highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality in HIV-1 infected patients [6]. However, the effectiveness of HAART can be compromised by the presence of drug resistance mutations (DRMs), resulting in virological failure. European, International AIDS society and treatment guidelines recommend ARV drug resistance testing for all HIV-1 infected patients before treatment initiation and after treatment failure. Moreover, guidelines recommend the use of genotyping in most routine clinical situations. Current genotyping can be performed below a viral load of 1000 c/mL [7, 8].

Standard genotypic drug-resistance testing in ARV-naïve persons involves testing for mutations in the protease (PRO) and reverse transcriptase (RT) regions in HIV-1 polymerase (*pol*). Although reports of transmission of INSTI-resistant virus are rare, as use of INSTIs increases, the potential for transmission of INSTI-resistant virus may also increase. Therefore, when INSTI resistance is suspected, providers should supplement standard baseline genotypic resistance testing with genotypic testing for resistance to this class of drugs [5].

In clinical practice, sequencing is usually performed using Sanger Sequencing (SS) which enables the detection of drug resistance mutations (DRMs) present in at least 20–30% of the viral population to be detected [9, 10]. However, DRMs occurring less frequently, called “minority variants”, are not detected using the SS method.

Recent Ultra-Deep Sequencing (UDS) or Next-Generation Sequencing (NGS) technologies are known to have, in the majority of cases, better sensitivity and reproducibility than the SS

method. NGS technologies perform millions of parallel sequencing reactions to generate many, typically short, reads per run. These technologies can detect and quantify low-frequency variants down to 5% of the total virus population [10–15].

The introduction of NGS into clinical laboratories has been slow for several reasons: (i) the impact on drug response and thus the clinical relevance of low-frequency DRMs before ART and after virological failure remains open to debate [14, 16–19], (ii) the high costs of this technology, (iii) the turnaround time and the number of samples per run.

Vandenhende M-A et al. [20] reported that low-frequency DRMs detected before ART initiation and after virological failure in patients receiving the first-line ART could increase the overall burden of resistance to PI, NRTI and NNRTI. More than two-thirds of these patients had additional low-frequency DRMs only detected by NGS. This observation is in accordance with previous studies that describe the abundance of low-frequency DRMs detected by NGS in treatment-naïve patients [21] as well as in treatment-experienced patients [14, 19, 22], in some cases changing the susceptibility to the prescribed treatment.

However, a recent study by Raymond S et al., using the NGS 454 GS-FLX system, showed that drug-resistant minority variants had no impact on the virological failure of treatment-naïve patients to a rilpivirine-based regimen [23].

Few studies have been conducted to compare and evaluate NGS and to determine its detection limit for HIV DRMs, to acquire expertise in performing analyses, or to collect data on which percentage of minority variants is predictive of treatment efficacy.

A few years ago, Mohamed and his team has compared HIV-1 DRMs minority variants after virological failure between SS and NGS. They demonstrated that NGS detected all mutations found by SS and identified also additional resistant variants [14].

Recently, Trabaud and his team [11] performed a prospective study in 100 clinical samples to compare SS and NGS (Roche 454 system) methods. Analyses were successful for 88% of samples regardless of HIV viral load or subtype. Setting the cut-off at 5% of minority variants for NGS seemed to be a good compromise to take into account the ability of NGS to detect low-prevalence DRMs, but without frequent reporting of mutations that are not detected by SS. With NGS, the authors identified additional PI resistance mutations. These mutations were mainly secondary mutations in treatment-naïve as well as in treatment-experienced patients. Moreover, RT mutations identified only by NGS were mainly observed in treated patients and were consistent with their drug treatment history.

The *Sentosa* SQ HIV genotyping assay (Vela-Diagnostics, Germany) is a novel deep-sequencing, *in vitro* semi-automated and standardised system. The objective of this study was to evaluate this novel NGS HIV-1 drug resistance monitoring system in a population of HIV-1 infected patients representative of those followed in clinical routine. More precisely, we analysed the repeatability (intra- and inter-run), the precision and the sensitivity of this NGS workflow. We also investigated DRMs and low-prevalence mutations detected by NGS compared to the SS as the reference method with the goal to accreditate this platform in our clinical routine.

## 2. Materials and methods

### 2.1 Patients

A total of 67 plasma samples collected from 40 patients (see details in Table 1) and previously tested using the routine SS assay at the AIDS Reference Laboratory in Brussels (Université catholique de Louvain) were analysed with the *Sentosa* SQ HIV genotyping assay (Vela Diagnostics, Germany). Selected samples represent the HIV-1 infected patients population followed at the AIDS Reference Laboratory. This retrospective observational study does not require any

**Table 1. Characteristics of patients population.**

| Characteristics   | n = 40              |
|-------------------|---------------------|
| Subtypes          |                     |
| B                 | 14                  |
| C                 | 11                  |
| A1                | 4                   |
| Other             | 11                  |
| Viral load (c/mL) |                     |
| Average           | 72442               |
| Median            | 699                 |
| Range             | 300–10 <sup>6</sup> |
| ART treatment     |                     |
| None              | 19                  |
| Interruption      | 4                   |
| NRTI/PI           | 6                   |
| NRTI-NNRTI/INI    | 8                   |
| NRTI/PI/INI       | 2                   |

ART: antiretroviral treatment, NRTI: nucleoside reverse transcriptase inhibitor, PI: protease inhibitor, NNRTI: non-nucleoside reverse transcriptase inhibitor, INI: integrase inhibitor

<https://doi.org/10.1371/journal.pone.0209561.t001>

agreement of an ethical committee. HIV-1 viral loads had previously been measured using the Abbott m2000 RealTime HIV assay (Abbott Diagnostics, France). The plasma specimens had been frozen and stored at -80°C until testing.

## 2.2 Sanger sequencing

Viral RNA was extracted from 1 mL of plasma sample at baseline and at virological failure using MagNA Pure Compact Nucleic Acid Isolation Kit I Large volume on MagnaPure compact automate (Roche Diagnostics, Belgium). A nested PCR was performed. The sequences of the amplification primers (internal PCR) were represented in the [Table 2](#).

The sequencing was performed using the big dye terminator v3.1 ready reaction mix on ABI3500 automated sequencer (Life technologies, Belgium). The PRO, RT and INT sequences were determined using SS according to the Stanford consensus method. Sequences were proof-read using the SmartGene HIV module (Lausanne, Switzerland) and the sequence editing was confirmed manually. Mutations compared to HIV-1 Consensus B reference were reported with this module as well as the drug resistance interpretation.

## 2.3 NGS using the Sentosa SQ HIV genotyping assay

The assay was performed according to the manufacturer's instructions (Vela-Dx, Germany). The Sentosa SQ HIV genotyping assay is reserved for the detection of HIV DRMs in PRO, RT and INT regions from plasma samples. The NGS workflow automates nucleic acid extraction from 730uL plasma samples and PCR set-up (Sentosa SX101), followed by an off-board PCR amplification (Veriti 96-well thermal cycler, Applied Biosystems). The workflow continues with normalisation, enzymatic shearing, purification and adapter ligation (Sentosa SX101). Finally, the two last steps consist of template preparation and sequencing, based on ion torrent technology (Sentosa ST101 and SQ301).

The assay contains several controls: a system control (SC), a positive and a negative control. The SC is added as a sample to control the entire workflow from RNA extraction to sequencing

**Table 2. Sequences of the amplification primers.**

|              |                                     |
|--------------|-------------------------------------|
| FWD-PRORT-I1 | 5' –CCAGARCAGRCCAGAGCCAACAGCCCCA–3' |
| FWD-PRORT-I2 | 5' –AGAGCCAACRGCCCCACC–3'           |
| REV-PRORT-I1 | 5' –TTCTGCTATTAATTCYTTTGCTGG–3'     |
| REV-PRORT-I2 | 5' –TTCTGCTAYTAAGTCTTTTGATGGRT–3'   |
| REV-PRORT-I3 | 5' –TTCAGCTATYAAGTCTTTTGATGG–3'     |
| FWD-INT-I1   | 5' TTCRGGATYAGAAGTAAAYATAGTAACAG–3' |
| REV-INT-I1   | 5' TCCTGTATGTCARACCCCAATATG–3'      |

FWD: forward primer; REV: reverse primer; PRORT: protease and reverse transcriptase; INT: integrase; I: internal PCR

<https://doi.org/10.1371/journal.pone.0209561.t002>

data analysis (functions as a positive control), as well as ensuring the absence of contamination in the workflow (functions as a negative control). An internal control (IC) is also added to each sample at the beginning of the extraction. The IC is a positive control for both nucleic acid extraction and library preparation steps. The third control is the Ion Dx CF-1 control, added during the emulsion. This control checks the steps of template preparation and sequencing.

## 2.4 Reference samples

A standard panel, HIV-1 drug resistance EQA (QCMD-2016) (n = 5), was purchased from Quality Control for Molecular Diagnostics (Glasgow, Scotland, UK). These external quality control samples were tested to assess HIV-1 protease and reverse transcriptase sequencing performances. Consensus sequences provided by QCMD were obtained by aligning the sequences of all participating laboratories, mainly European laboratories in the HIV field. A sample from INSTAND-2015 (n = 1) (Instand, Düsseldorf, Germany) external quality control was tested to control the integrase region. We also tested an 8E5 HIV positive cell line, derived from LAV-infected cells, a CD4<sup>+</sup> CEM-derived human T-cell line (obtained from the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH) as an internal quality control (IQC) (diluted in HIV-negative plasma).

## 2.5 Study design

The HIV-1 subtype and drug resistance analysis were determined in 67 clinical specimens and standard panel members by in house SS assay. These results were compared with those generated by Sentosa SQ HIV genotyping assay. Samples were previously genotyped on ABI3500 automated sequencer (Life Technologies, Belgium) and sequences were analysed with IDN-S-HIV1 SmartGene module (Lausanne, Switzerland).

## 2.6 Data interpretation

FASTA sequences were compared using raw data from Sentosa-Vela.

DRMs (as well as reads, coverage) and drug resistance reports were compared by exporting raw FASTQ sequences from Vela and analysing them with the specific UDS-HIV SmartGene module, IDNS-ASP (Lausanne, Switzerland). Reads were filtered to eliminate low quality reads (elimination of short sequences, excision of primers sequences alignments). An ambiguity filter was used in order to remove uncertain nucleotides. This process is automated and the final alignment can be finally visualised.

An interpretation of the genotypic drug resistance report, by using the Stanford 8.4.0 algorithm, was generated with detected mutations and their percentages. The nucleotide ambiguity

filter was set at 0.5% and the threshold for interpretation of resistance at 5% when the position was covered by at least 50 reads.

## 2.7 Statistical analysis

The proportions of mutations detected by NGS and SS, categorised according to the percentage of minority variants population, were compared using the ANOVA-test ( $p < 0.05$ ).

## 3 Results

### 3.1 Repeatability

Intra-assay repeatability was evaluated by analysing patient samples twice in a single run ( $n = 3$ ) (Table 3). Inter-assay repeatability was evaluated by analyzing patient samples twice in two different runs ( $n = 6$ ) (Table 4).

All real mismatches were at the end of the sequences and as a consequence did not affect the drug resistance reports.

All mutations (non-DRMs and DRMs) were correctly identified with SS and NGS methods. The NGS has identified some DRMs, who were not identified by SS method, in only one of the duplicates (see Tables 3 and 4). The recommended criteria of Vela-Dx for the accurate detection of targeted mutation are a variant frequency of 20% at 1000 c/mL or of 5% at 4000 c/mL and were fulfilled for two of three samples.

The criteria of Vela-Dx were not fulfilled for only one sample. Indeed, despite a viral load  $> 1000$  c/mL and correct coverage at this position, a mutation presents at 32% ( $> 20\%$ ) was not detected in one of the duplicates. This discordant result (for DRMs and drug resistance reports) is reported in the section 3.6 and in the discussion section.

8E5 IQC was used to evaluate the reproducibility. Indeed, one mutation was followed in each region; PRO, RT and INT regions (Table 5). More precisely, the mutations (non-DRMs) PRO18E, RT379C and INT265V were followed. For each mutation, a variation of  $\pm 5\%$  around the average was accepted. The three mutations were identified within acceptability limit.

### 3.2 Precision

A total score of 340/340 was obtained for the QCMD-2016 (01–05) external quality controls for HIV-1 PRO and RT regions (Table 6). The QCMD proficiency program assigns one point for an identical codon to the consensus sequence and one point if at least one amino acid is identical to the consensus sequence. For the INSTAND-2015 external quality control, the INT sequence obtained using NGS was 100% identical to that obtained using the SS method (Table 7).

Three of five QCMD-2016 samples presented resistance mutations (Table 8). All DRMs were correctly identified with SS and NGS methods.

Moreover, 8E5 IQC was diluted successively 1/2, 1/5 and 1/10 (serial dilutions) and compared to SS results. All mutations found in SS were correctly identified with NGS. We obtained 100% of sequences homology, with no mismatch. Moreover, there was no difference in resistance reports between SS and NGS methods (date not shown).

### 3.3 Analytical sensitivity

The limit of detection (LOD) was estimated with the 8E5 IQC. IQC was diluted to obtain a viral load of 200 and 100 c/mL (Table 9), with as the acceptance criteria of at least 95% of success rate. No acceptable result was obtained for a viral load of 100 c/mL ( $n = 2$ ). The

Table 3. Intra-assay repeatability.

| Sample *<br>(vL c/mL) | All mutations identified with SS and NGS                                                                                                                                                                                                                                                                                                                                                                                     | DRMs identified with SS and NGS | DRMs identified with NGS (%) in one duplicate | Drug resistance reports with NGS in one duplicate                         |
|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|-----------------------------------------------|---------------------------------------------------------------------------|
| V15-1676<br>(2229)    | PRO: 11I, 13V, 16E, 17E, 20R, 35D, 36I, 37D, 60E, 62V, 63T, 69K, 89I, 93L<br>RT: 35T, 60I, 107S, 122E 123G, 142V, 177E, 178L, 200A, 202V, 207A, 211K 214L, 244V, 245Q, 272P, 277R, 282I, 286A, 291D, 292I, 293V, 310I, 312G, 317A, 335D, 356K, 359S, 379C, 379G,<br>INT: 17N, 20K, 24N, 31I, 68V, 72V, 74I, 112V, 124A, 125A, 127R, 134D, 136Q, 136R, 138D, 188R, 201I, 218L, 221H, 222K, 234I, 256E, 265V, 268L             | /                               | RT: M41L (31.9%)                              | Low-level resistance to AZT, D4T<br>Potential low-level resistance to DDI |
| V16-2178<br>(1996)    | PRO: 10V, 15V, 20R, 35D, 36I, 41K, 57K, 63T, 65D, 77I, 89M<br>RT: 14S, 35T, 39A, 40D, 60I, 67N, 69D, 70R, 98G, 106G, 123E, 135L, 162H, 173T, 174K, 195L, 200A, 203D, 207A, 211K, 219Q, 228H, 245Q, 248D, 272P, 272S, 291D, 292I, 293V, 294T, 297T, 326V, 334E, 345I, 356K, 359S, 366R, 377M, 379C, 379G<br>INT: 11D, 13D, 14R, 20K, 101I, 112R, 124S, 125A, 136Q, 146H, 158F, 193E, 201I, 205S, 218I, 234V, 256E, 279G, 283G | RT: 67N, 69D, 70R, 98G, 219Q    | RT: L100V (6.3%)                              | Different score of resistance to all NNRTI, Low-level resistance to ETR   |
| V17-1123<br>(9480)    | PRO: 19I, 41K, 45R, 46I, 53L, 60E, 62V, 63P, 77I, 85V, 92E, 92K<br>RT: 49R, 50V, 60I, 83K, 162H, 162Y, 177N, 207K, 211T, 272P, 275R, 278N, 281R, 286A, 297K, 333E, 357V, 379C, 379G<br>INT: 124A, 124N, 154I, 182V, 201I, 256E                                                                                                                                                                                               | PRO: 46I, 53L                   | /                                             | /                                                                         |

VL: viral load, NGS: Next-Generation Sequencing, DRMs: Drug Resistance Mutations, PRO: protease, RT: reverse transcriptase, INT: integrase, AZT: Zidovudine, D4T: stavudine, DDI: didanosine, NNRTI: non-nucleoside reverse transcriptase inhibitor, ETR: etravirine

\* patient sample was evaluated twice

<https://doi.org/10.1371/journal.pone.0209561.t003>

sequencing of INT region was failed. The coverage for PRO and RT regions were in warning status with very low values (42–539). 50% of success rate for a viral load of 200c/mL was obtained ( $n = 2$ ). INT region was successfully sequence but the coverage for PRO and RT regions appeared in warning status (94–593).

Based on this IQC analysis, patient samples ( $n = 10$ ) with a viral load between 285 to 975 c/mL (different subtypes, ARV therapy naive or experienced) were selected to establish a LOD. The viral loads 3-fold lower than analytical sensitivity established by Vela Dx (1000 c/mL) were evaluated. All samples were appropriately amplified and sequenced (in term of number of reads and coverage) and the LOD was set at 300 c/mL (Table 9). The warning status appeared for some samples for which, a specific attention has been made in checking at each position.

### 3.4 Comparison between SS and NGS methods

This comparison allows the evaluation of the ability of detecting a mutation in one assay compared the other. A total of 614 differences were identified in the 41 samples (40 HIV-1 infected patients and one IQC) (Table 10), using the NGS method compared to the SS method, among which 257 (41.86%) were minority variants (between 5 to 20%). More precisely (Fig 1), 138 differences (53.7%) were present with a frequency between 5 and 10%, 68 (26.46%) at >10 to 15%, 51 (19.84%) at >15 to 20% and 357 (58.14%) samples had mutations with a frequency >20%. Moreover, 530/614 (86.3%) of these differences were present in the RT region, 46/614 (7.5%) in the PR region and 38/614 (6.2%) in the INT region.

There were 60 differences identified using the SS method compared to the NGS method (Table 10). These differences were classified into three categories. In the first category, 46/60 (76.87%), we included sequences with a high background interference at the baseline

**Table 4. Inter-assay repeatability.**

| Sample *<br>(vL c/mL) | All mutations identified with SS and NGS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | DRMs identified SS<br>and NGS                 | DRMs identified with<br>NGS (%) in one duplicate | Drug resistance reports<br>with NGS in one duplicate |
|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------|--------------------------------------------------|------------------------------------------------------|
| V16-7289<br>(1550)    | PRO: 13V, 14R, 15V, 20I, 36I, 39Q, 63T, 69K, 82I, 89M<br>RT: 21I, 35T, 50V, 60I, 102Q, 122E, 123N, 142V, 162N, 173T, 174K, 177E, 178L, 200A, 207D, 211K, 245Q, 250E, 272P, 283I, 292I, 293V, 297A, 326V, 329V, 334L, 335D, 346Y, 356K, 357R, 358G, 359A, 359S, 371V, 379C, 379G<br>INT: 14R, 31I, 50I, 63I, 72V, 74I, 101I, 112V, 124A, 125A, 134D, 135V, 136T, 181L, 201I, 206S, 218S, 234I, 254T, 254insert, 255insert, 255K, 255N, 256E, 283G                                                                                                                                                                                                                          | /                                             | RT: D67N (6.9)                                   | Low-level resistance to<br>AZT, D4T                  |
| V16-7338<br>(91971)   | PRO: 12S, 14R, 15V, 19I, 37S, 41K, 63M, 69K, 77I, 82I, 89M, 93L<br>RT: 35T, 36A, 39E, 48T, 69A, 104R, 162C, 173A, 174K, 177E, 178M, 200A, 203D, 207D, 207N, 210S, 211K, 245Q, 248D, 248N, 250E, 251N, 272P, 275Q, 291D, 292I, 293V, 294T, 329L, 334D, 335D, 356K, 359N, 376S, 377V, 379C, 379G<br>INT: 11D, 24N, 25E, 31I, 100Y, 101I, 112V, 112I, 124A, 125A, 136Q, 162V, 163A, 163Q, 201I, 234I, 278A, 283G, 289Q                                                                                                                                                                                                                                                       | /                                             | /                                                | /                                                    |
| V17-0688<br>(3685)    | PRO: 12A, 14R, 15V, 16A, 16E, 19I, 35D, 36I, 37D, 51E, 57K, 60E, 61D, 61E 63T, 65D, 67E, 69K, 72T, 77I, 89M<br>RT: 4T, 6D, 8I, 35T, 35E, 35K, 39M, 40D, 49R, 83K, 99, 103N, 122E, 123N, 137S, 138A, 142T, 159V, 162H, 173T, 177E, 178L, 179I, 184V, 196E, 200E, 202V, 207E, 207N, 211K, 225H, 237E, 238T, 245Q, 248D, 250E, 272P, 277R, 286A, 291D, 292I, 293V, 294S, 297A, 297K, 301F, 311R, 314M, 324E, 329V, 334E, 335S, 335D, 356K, 357R, 357T, 359T, 366R, 371V, 377V, 379C, 379G<br>INT: 11D, 14R, 17N, 21T, 31I, 45V, 72V, 91T, 101I, 111R, 112V, 119P, 122I, 124A, 125A, 134D, 136Q, 157Q, 160T, 160N, 167E, 173R, 201I, 203M, 208L, 212L, 234V, 256E, 260I, 283G | RT: 103N, 138A, 184V, 225H, 238T<br>INT: 157Q | /                                                | /                                                    |
| V17-1006<br>(31090)   | PRO: 13V, 14R, 37S, 63P, 72V, 77I<br>RT: 36D, 118I, 123E, 135R, 142V, 162C, 179I, 196E, 211G, 215E, 245K, 292I, 293V, 356K, 357R, 357I, 360T, 366R, 370D, 377I, 377L, 379C, 379G<br>INT: 17N, 45V, 45I, 100Y, 101I, 111R, 112I, 119P, 163A, 201I, 206S, 211R, 219N, 253E, 255G, 256E, 279G, 288G                                                                                                                                                                                                                                                                                                                                                                          | 215E                                          | /                                                | /                                                    |
| V17-1092<br>(975)     | PRO: 13V, 14R, 20I, 36I, 37D, 38I, 41K, 63P, 64V, 67Y, 69K, 89I<br>RT: 27S, 35T, 36D, 60I, 68N, 135V, 162A, 173T, 174E, 177E, 178V, 200A, 207E, 245Q, 272S, 274V, 277R, 286A, 291D, 293V, 294T, 322T, 326R, 328D, 335D, 356K, 357K, 359S, 366R, 369A, 370K, 371V, 375V, 379C, 379G<br>INT: 3N, 14R, 21T, 39N, 65R, 68V, 84M, 101I, 112V, 124A, 125A, 134N, 135V, 136T, 201I, 206S, 208M, 265V, 283G                                                                                                                                                                                                                                                                       | /                                             | /                                                | /                                                    |
| V17-1123<br>(9480)    | PRO: 19I, 41K, 45R, 46I, 53L, 60E, 62V, 63P, 77I, 85V, 92E, 92K<br>RT: 49R, 50V, 60I, 83K, 162H, 162Y, 177N, 207K, 211T, 272P, 275R, 278N, 281R, 286A, 297K, 333E, 357V, 379C, 379G<br>INT: 124A, 124N, 154I, 182V, 201I, 256E                                                                                                                                                                                                                                                                                                                                                                                                                                            | 46I, 53L                                      | /                                                | /                                                    |

VL: viral load, NGS: Next-Generation Sequencing, DRMs: Drug Resistance Mutations, PRO: protease, RT: reverse transcriptase, INT: integrase, AZT: Zidovudine, D4T: stavudine

\* patient sample was evaluated twice

<https://doi.org/10.1371/journal.pone.0209561.t004>

(background sequencing signal), manual correction mistakes, only one strand of reads (forward or reverse) or when the mutation was weakly present. In the second category, 9/60 (18.33%), the observed differences reflected that NGS distinguished cases when combinations of a codon were really present compared to SS. NGS could discern exact mixtures of more than two amino acids, whereas SS could not. Finally, the last category, 5/60 (15%), represented the situation where the mutation was indeed present.

Table 5. 8E5 internal quality control reproducibility.

| Sample | Reads  | % PRO 18E | % CL PRO 18E | % LCL PRO 18E | % UCL PRO 18E | % RT 379C | % CL RT 379C | % LCL RT 379C | % UCL RT 379C | % INT 265V | % CL INT 265V | % LCL INT 265V | % UCL INT 265V |
|--------|--------|-----------|--------------|---------------|---------------|-----------|--------------|---------------|---------------|------------|---------------|----------------|----------------|
| IQC-1  | 47034  | 5,5       |              |               |               | 14,0      |              |               |               | 93,0       |               |                |                |
| IQC-2  | 86736  | 3,0       |              |               |               | 15,4      |              |               |               | 94,9       |               |                |                |
| IQC-3  | 211696 | 1,9       |              |               |               | 15,2      |              |               |               | 92,8       |               |                |                |
| IQC-4  | 112359 | 2,9       |              |               |               | 16,4      |              |               |               | 95,2       |               |                |                |
| IQC-5  | 76572  | 2,8       |              |               |               | 17,3      |              |               |               | 94,4       |               |                |                |
| IQC-6  | 165896 | 1,9       |              |               |               | 16,1      |              |               |               | 96,5       |               |                |                |
| IQC-7  | 247282 | 2,9       |              |               |               | 15,2      |              |               |               | 97,1       |               |                |                |
| IQC-8  | 80727  | 2,1       |              |               |               | 16,2      |              |               |               | 94,2       |               |                |                |
| IQC-9  | 102860 | 1,8       |              |               |               | 19,0      |              |               |               | 95,6       |               |                |                |
| IQC-10 | 144248 | 1,9       | 2,7          | -2,3          | 7,7           | 16,1      | 16,1         | 11,1          | 21,1          | 94,7       | 94,8          | 89,8           | 99,8           |

IQC: internal quality control, PRO: protease, RT: reverse transcriptase, INT: integrase, CL: average percentage of the mutation: LCL: lowest average percentage of the mutation (-5%), UCL: uppest average percentage of the mutation (+5%)

<https://doi.org/10.1371/journal.pone.0209561.t005>

We detected 1516 mutations that were identified with both methods (SS and NGS), 357 of which (23.55%) were minority variants (frequency between 5 and 20%).

Drug resistance interpretation from the SS and NGS data was compared using the Stanford 8.4.0 algorithm (Fig 2A, 2B & 2C). Among the 41 samples, 33 (80.5%) had identical drug resistance interpretation reports. Discrepant results were obtained for 8 samples. Five of these samples had DRMs (minority variants) with an allelic frequency below the LOD of the SS method (6.3 to 20.5%) and are represented in the Table 11.

One mutation was only identified by NGS at 66.2%, the 138A, conferring resistance to Raltegravir (RAL), Elvitegravir (EVG) and Dolutegravir (DTG). The analysis of electropherograms revealed that this mutation was only present in the forward strand and therefore was not taken into account in the interpretation. The analysis was repeated a second time (undiluted) and the mutation was confirmed.

Two mutations were only identified by the SS method. The first DRM was the 263K, conferring resistance to Raltegravir (RAL), Elvitegravir (EVG) and Dolutegravir (DTG). The analysis of SS electropherograms revealed that the background was high. The analysis was repeated (undiluted and diluted 1/10) and in both cases this mutation was not really present. Moreover, the importance of this DRM remains unclear according to the interpretation algorithms. The second DRM was the 103N (conferring resistance to Efavirenz and Nevirapine), the SS analysis

Table 6. QCMD precision.

| Sample    | SS Clade | NGS Clade | Score | Difference: SS nt(aa)—NGS nt(aa)                     |
|-----------|----------|-----------|-------|------------------------------------------------------|
| ENVA16-01 | C        | C         | 68/68 | RT103: AAA (K)—RAA (K/E)<br>RT190: GGA (G)—GRA (G/E) |
| ENVA16-02 | C        | C         | 68/68 | None                                                 |
| ENVA16-03 | B        | B         | 68/68 | RT179: GTT (V)—GYT (V/A)                             |
| ENVA16-04 | C        | C         | 68/68 | PRO71: GCT (A)—RCT (A/T)                             |
| ENVA16-05 | D        | D         | 68/68 | PRO71: GCT (A)—RCT (A/T)<br>RT103: AAA (K)—RAA (K/E) |

SS: sanger sequencing, NGS: next-generation sequencing, nt: nucleotide, aa: amino-acid, PRO: protease, RT: reverse transcriptase

<https://doi.org/10.1371/journal.pone.0209561.t006>

Table 7. INSTAND precision.

| Sample            | SS clade | NGS clade | Criteria                                                           | SS Result                    | Success rate (number of participating labs) | NGS result                   |
|-------------------|----------|-----------|--------------------------------------------------------------------|------------------------------|---------------------------------------------|------------------------------|
| 384–003 (INSTAND) | B        | B         | Number of different nt by 100 nt of the INSTAND consensus sequence | <6,5                         | 100% (29/29)                                | 0                            |
|                   |          |           | Determination of DRMs                                              | N155H<br>G163R<br>S230N      | 100% (30/30)                                | N155H<br>G163R<br>S230N      |
|                   |          |           | Resistance interpretation                                          | DTG: S/I<br>EVG: R<br>RAL: R | 100% (31/31)                                | DTG: S/I<br>EVG: R<br>RAL: R |

SS: sanger sequencing, NGS: next-generation sequencing, nt: nucleotide, DRMs: Drug Resistance Mutations, DTG: dolutegravir, EVG: elvitegravir, RAL: raltegravir

<https://doi.org/10.1371/journal.pone.0209561.t007>

showed that this mutation was indeed present. At this time, the possible explanation was the non-detection of a minority variant <20% for a viral load <1000 c/mL.

In the 8 discrepant results, 6/8 (75%) were RT mutations, with a 50:50 proportion of NRTI/NNRTI.

### 3.5 FASTA sequence comparison between SS and NGS

FASTA sequences using SS and NGS were compared for 40 samples and 6 external quality controls (see details in Table 12).

We obtained some gaps, corresponding to the difference in length of sequences, with the average of 240 pb. Total mismatches, counting minority variants not found with SS and NGS, have an average of 21. Moreover, we obtained 99.9% of real sequence homology and one real mismatch.

### 3.6 Minority variants

The first parameter evaluated was fidelity and we analysed low-prevalence DRMs. The second parameter investigated was the presence of lower concentration DRMs (IQC and samples

Table 8. Interpretation report of QCMD resistant samples.

| Sample    | Clade | DRMS identified with SS and NGS (%)                                                                                      | Drug resistance report                                                                                                                         |
|-----------|-------|--------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|
| ENVA16-01 | C     | PRO: 46I (99.5), 54V (98.6), 82A (91.8)<br>RT: 184V (100), 190E (7.7)                                                    | High level: 3TC, FTC, EFV, NVP, RPV, ATV, FPV, IDV, LPV, NFV, SQV<br>Intermediate: ETR, FPV<br>Low level: ABC, TPV<br>Potential low-level: ddi |
| ENVA16-02 | C     | RT: 41L (99.4), 44D (39), 67N (99.8), 69D (100), 98G (100), 184I (100), 188L (100), 190A (100), 210W (100), 215Y (94.3), | High level: 3TC, ABC, AZT, D4T, ddi, FTC, TDF, EFV, NVP, RPV<br>Intermediate: ETR                                                              |
| ENVA16-04 | C     | RT: 67N (97.3), 70R (99.1), 184V (98.4), 219Q (100)                                                                      | High level: 3TC, ABC, FTC<br>Intermediate: AZT, D4T, ddi<br>Low level: TDF                                                                     |

PRO: protease, RT: reverse transcriptase, 3TC: lamivudine, FTC: emtricitabine, EFV: efavirenz, NVP: nevirapine, RPV: rilpivirine, ATV: atazanavir, FPV: fosamprenavir, IDV: indinavir, LPV: lopinavir, NFV: nevirapine, SQV: saquinavir, ETR: etravirine, ABC: abacavir, TPV, tipranavir DDI: didanosine, AZT: zidovudine, D4T, stavudine, TDF: tenofovir

<https://doi.org/10.1371/journal.pone.0209561.t008>

**Table 9. Analytical sensitivity of internal quality control and samples.**

| Sample                    | Viral load (c/mL) | Subtypes | Number of reads PR/RT/INT | Coverage status (value)                                                            |
|---------------------------|-------------------|----------|---------------------------|------------------------------------------------------------------------------------|
| IQC-200_1                 | 200               | B        | 40865                     | -Passed INT<br>-Warning PRO & RT (94–470)                                          |
| IQC-200_2                 | 200               | B        | 56708                     | -Passed INT<br>-Warning PRO & RT (133–593)                                         |
| IQC-100_1                 | 100               | B        | 71340                     | -Warning PRO & RT (129–539)<br>-Failed INT                                         |
| IQC-100_2                 | 100               | B        | 7513                      | -Warning PRO & RT (42–378)<br>-Failed INT                                          |
| V16-1757<br>Dilution 1/10 | 285               | G        | 161246                    | -Passed                                                                            |
| V17-2597                  | 300               | C        | 25745                     | -Warning PRO (510 to 996)<br>-Warning RT (421 to 663)<br>-Warning INT (730 to 992) |
| V16-2001                  | 494               | A1       | 61429                     | -Warning PRO (547–878)                                                             |
| V16-1638                  | 620               | A1       | 96226                     | -Passed                                                                            |
| V16-0052                  | 669               | B        | 56186                     | -Warning all INT (301–742)                                                         |
| V16-4015                  | 724               | CRF02AG  | 31661                     | -Warning PRO (406–990)<br>-Warning RT (513–982)<br>-Warning INT (566–972)          |
| V17-0521                  | 778               | A1U      | 46352                     | -Warning PRO (455–915)<br>-Warning INT (576–929)                                   |
| V11-6747<br>Dilution 1/2  | 808               | C        | 111983                    | -Warning INT (683–960)                                                             |
| V16-0300                  | 861               | D        | 74007                     | -Passed                                                                            |
| V17-1092                  | 975               | CRF02AG  | 73961                     | -Warning PRO (852–983)                                                             |

IQC: internal quality control, PRO: protease, RT: reverse transcriptase, INT: integrase, Passed: coverage > 1000, Warning: coverage between 50 and 1000, Failed: coverage < 50

<https://doi.org/10.1371/journal.pone.0209561.t009>

diluted). In both cases, we analysed low-prevalence DRMs that were undetected in one of the duplicates (Table 13).

The criteria of Vela-Dx were not fulfilled for only one sample. Indeed, despite a viral load > 1000 c/mL and correct coverage at this position, a mutation presents at 32% (>20%) was not detected in one of the duplicates. The analysis of the Bam files (raw data from the sequencer) by Vela-Dx revealed that this sample had at least three virus subpopulations. In the duplicate in which the mutation could not be detected, only two subpopulations could be amplified. In addition, this specific mutation was not identified with SS method.


Vela Dx criteria were fulfilled for other samples evaluated. Indeed, DRMs present at > 20% were detected for viral loads of 1000 c/mL, those >5% and <20% were detected randomly for viral loads below < 4000 c/mL.

**Table 10. Comparison of mutations between Sanger Sequencing and Next-Generation Sequencing.**

|    | NGS |      |
|----|-----|------|
| SS | 0   | 1    |
| 0  | /   | 614  |
| 1  | 60  | 1516 |

SS: sanger sequencing, NGS: next-generation sequencing, 0: absence of mutation 1: Presence of mutations

<https://doi.org/10.1371/journal.pone.0209561.t010>




**Fig 1. Proportion of minority variants detected by Next-Generation Sequencing.** Proportion of minority variants detected by Next-Generation Sequencing. The proportion of mutations (%) is reported by minority variants population detected (%). In black: between 5 and 10%, in dark grey: between 10 and 15%, in light grey: between 15 and 20% and in white: >20%. \* $p<0.05$ , \*\* $p<0.01$ , \*\*\* $p<0.001$ .

<https://doi.org/10.1371/journal.pone.0209561.g001>

## 4. Discussion

ARV drug resistance testing is recommended for all HIV-1 infected patients before treatment initiation and after treatment failure [7, 8]. In clinical practice, ARV drug resistance is assessed using the SS reference method, which can detect DRMs that are present in at least 20–30% of the viral population [9]. However, DRMs that are present below these values and called



**Fig 2. a-b & -c: Drug resistance interpretation reports with the resistance of drug mutations between Sanger Sequencing and Next-Generation Sequencing.** Drug resistance interpretation reports with the resistance of drug mutations between Sanger Sequencing and Next-Generation Sequencing. Comparison of drug resistance interpretation reports (in purple) and Drug Resistance Mutations (in red) between Sanger Sequencing and Next-Generation Sequencing. SS: Sanger Sequencing.

<https://doi.org/10.1371/journal.pone.0209561.g002>

**Table 11. Drug resistance mutations and reports obtained by Next-Generation Sequencing.**

| Sample   | DRMs (region) (%)                   | Difference in resistance reports                                                                                   |
|----------|-------------------------------------|--------------------------------------------------------------------------------------------------------------------|
| V11-6747 | 46I (PRO) (6.8)                     | -Potential low-level: ATV, FPV, IDV, LPV, SQV<br>-Intermediate: NFV                                                |
| V15-6348 | 20T (PRO) (20.5)                    | -Low-level: NFV                                                                                                    |
| V16-2178 | 100V (RT) (6.3) (associated to 98G) | -Low-level: ETR<br>-Intermediate: RPV<br>-Low-level: ETR<br>-High level: NVP                                       |
| V16-6496 | 69D (RT) (7.1)<br>70E (RT) (10)     | -Potential low-level resistance: 3TC, FTC<br>-Low-level resistance: ABC, D4T, TDF<br>-Intermediate resistance: DDI |
| V17-0297 | 179D (RT) (6.1) (associated to 98G) | -Low-level resistance: EFV, ETR, RPV                                                                               |

DRMs: drug resistance mutations, PRO: protease, RT: reverse transcriptase, ATV: atazanavir, FPV: fosamprenavir, IDV: indinavir, LPV: lopinavir, SQV: saquinavir, NFV: nevirapine, ETR: etravirine, RPV: rilpivirine, NVP: nevirapine, 3TC: lamivudine, FTC: emtricitabine, ABC: abacavir, D4T: stavudine, TDF: tenofovir, DDI: didanosine, EFV: efavirenz

<https://doi.org/10.1371/journal.pone.0209561.t011>

“minority variants”, are not detected using the SS method. NGS technologies allows the detection of low frequency HIV-1 DRMs and have potential advantages in improving patient follow-up.

The *Sentosa* SQ HIV genotyping assay by Vela-Dx is a new, automated NGS-based assay that is user friendly without specialised skills and is standardised. The present study provided an evaluation of this novel NGS HIV-1 drug resistance monitoring system in HIV-1 infected patients and compared it with the SS reference method. This evaluation provided interpretable data for samples regardless of viral loads, virus subtypes or patient history.

The LOD of the NGS *sentosa* assay was established at 300 c/mL. This limit was three-fold lower compared to the analytical sensitivity established by Vela-Dx (1000 c/mL).

Moreover, and in accordance to several publications [9, 10], we can confirm that the sensitivity of the NGS assay is higher than that of the SS method.

The criteria of Vela-Dx were not fulfilled for one discordant result concerning the intra-run repeatability. Indeed, despite a viral load >1000 c/mL and correct coverage at this position, a mutation presents at 32% (>20%) was not detected in one of the duplicates.

**Table 12. Comparison of FASTA sequences between Sanger Sequencing and Next-Generation Sequencing.**

| Gene                    | PRO-RT & INT (n = 57) |      |      |
|-------------------------|-----------------------|------|------|
|                         | min                   | X    | max  |
| Length of sequence (pb) | 1088                  | 1385 | 1596 |
| Gaps                    | 174                   | 240  | 678  |
| Total mismatches *      | 0                     | 21   | 69   |
| Real mismatch           | 0                     | 1    | 4    |
| % of homology *         | 92.0                  | 98.2 | 100  |
| % of real homology      | 99.7                  | 99.9 | 100  |

PRO: protease, RT: reverse transcriptase, INT: integrase, min: minimum of values, X: average, max: maximum of values

\* counting minority variants not found as mismatching

<https://doi.org/10.1371/journal.pone.0209561.t012>

**Table 13. Evaluation of low-prevalence Drug-Resistance Mutations by Next-Generation Sequencing.**

| Sample                | Viral load (c/mL) | Discrepant DRM | % 1  | Coverage 1 | % 2 | Coverage 2 |
|-----------------------|-------------------|----------------|------|------------|-----|------------|
| V15-1676              | 2229              | RT: 41L        | 31.9 | 3060       | 0   | 1759       |
| V16-2178              | 1996              | RT: 100V       | 6.3  | 9626       | 0   | 3863       |
| V16-7289              | 1550              | RT: 67N        | 0    | 478        | 6.9 | 5922       |
| V17-0688              | 3685              | RT: 238T       | 8.8  | 4743       | 0   | 7690       |
| V11-6747              | 1616              | RT: 184I       | 28.7 | 2536       | 0   | 1034       |
| V11-6747 Dilution 1/2 | 808               | PRO: 46I       | 0    | 3649       | 6.8 | 561        |

DRM: Drug Resistance Mutation, PRO: protease, RT: reverse transcriptase, %1: percentage in the first duplicate, %2: percentage in the second duplicate

<https://doi.org/10.1371/journal.pone.0209561.t013>

The analysis of the raw data from the sequencer revealed that this sample had at least three virus subpopulations. In the duplicate in which the mutation could not be detected, only two subpopulations could be amplified. In addition, this specific mutation was not identified with SS method.

The comparison between the two methods (SS and NGS) demonstrated that nearly half (41.86%) of the differences in the mutations identified by NGS were minority variants (occurring at frequencies of 5 to 20%). Only 23.55% of mutations were minority variants that were detected by both methods, highlighting that NGS detects twice as many minority variants, as does SS. Moreover, the majority of these mutations (86.3%) were located in the RT region.

A total of 60 mutations were only found with the SS reference method. The detection of most of these (76.87%) can be explained by the fact that the SS method remains a subjective expertise test, especially when the quality of sequences is poor, which may lead to divergent results. A small proportion of these differences (15%) may be explained by the co-existence of variants, generating SS electropherograms that can often be confusing. NGS can distinguish combinations where a codon is really encoded and can discern exact mixtures of more than two amino acids, which is not possible with SS.

The comparison of DRMs, by interpretation of drug resistance reports, confirmed that NGS more frequently detected minority variants, 75% of which were present in the RT region. This observation is in accordance with several studies that describe the abundance of low-frequency DRMs detected by NGS in treatment naive patients [21] as well as in treatment-experienced patients [14, 19, 22]. Furthermore, RT DRMs identified only by NGS were mainly identified in treated patients and were consistent with their drug treatment history.

Among the analysed samples, 80.5% had identical drug resistance reports by NGS and SS methods. Discrepant results were obtained for 8 samples. Five of these samples presented minority variants with an allelic frequency below the limit of detection of the SS method. One mutation was only identified by NGS with an allelic frequency of 66.2%, the RT 138A. The analysis of electropherograms revealed that this mutation was only present in the forward strand and therefore was not taken into account in the interpretation. Two mutations were only identified by the SS. The first DRM was the INT 263K. The analysis of electropherograms revealed that the background was high (background sequencing signal) and this mutation was not really present. The second DRM was the RT 103N, the SS analysis showed that this mutation was indeed present. At this time, the most probable explanation was a problem linked to this specific sample.

At the 5% threshold for reporting minority variants, NGS appeared to attain an increased sensitivity for detecting low-frequency DRMs without compromising sequence accuracy for viral load >1000 c/mL.

Moreover, using this NGS assay, we identified novel DRMs that affected the HIV-1 drug resistance interpretation report and may have a clinical impact.

This study has some limitations including that the platform was evaluated using a limited number of retrospective HIV-1 patient samples and discordant results were observed for minority variant DRMs and with low viral load.

In conclusion, this is the first clinical evaluation of the *Sentosa* SQ HIV Genotyping Assay in a clinical laboratory in Belgium. The NGS appears to be a promising tool for the detection and quantification of DRMs in HIV-1 infected patients. Use of NGS for resistance genotyping can provide useful information in routine clinical practice. Further studies assessing the clinical relevance of low-prevalence DRMs are needed.

## Acknowledgments

The authors wish to thank the SmartGene team, especially Mr Elmer S. and Ms Loutan D., for providing free access to their HIV software package and for their help in the sequence analyses. We wish also to thank the Vela Diagnostics staff, particularly Mr Demillecamps E., Ms Buxa S., Ms Lucke J. and Mr Demirdjian R., for their availability and for their technical support.

## Author Contributions

**Conceptualization:** Géraldine Dessilly, Léonie Goeminne, Anne-thérèse Vandenbroucke.

**Methodology:** Géraldine Dessilly.

**Supervision:** Géraldine Dessilly, Benoît Kabamba-Mukabi.

**Validation:** Géraldine Dessilly.

**Writing – original draft:** Géraldine Dessilly, Léonie Goeminne, Francois E. Dufrasne, Anandi Martin, Benoît Kabamba-Mukabi.

**Writing – review & editing:** Géraldine Dessilly, Francois E. Dufrasne, Benoît Kabamba-Mukabi.

## References

1. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). *Science*. 1983; 220(4599):868–71. PMID: [6189183](#).
2. Gallo RC, Sarin PS, Gelmann EP, Robert-Guroff M, Richardson E, Kalyanaraman VS, et al. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). *Science*. 1983; 220(4599):865–7. PMID: [6601823](#).
3. Sasse A, Deblonde J., Jamine D., Ost C., Van Beckhoven D.. *Epidémiologie du SIDA et de l'infection à VIH en Belgique*. Institut Scientifique de Santé Publique /Wetenschappelijk Instituut Volksgezondheid INFECTIEUSES SEDM; 2017.
4. ONUSIDA. *Statistiques mondiales sur le VIH 2016*.
5. *Guidelines for the use of Antiretroviral agents in Adults and Adolescents Living with HIV (2018)*.
6. Palella FJ Jr., Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. *N Engl J Med*. 1998; 338(13):853–60. <https://doi.org/10.1056/NEJM199803263381301> PMID: [9516219](#).
7. Hammer SM, Eron JJ Jr., Reiss P, Schooley RT, Thompson MA, Walmsley S, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. *JAMA*. 2008; 300(5):555–70. <https://doi.org/10.1001/jama.300.5.555> PMID: [18677028](#).
8. Vandamme AM, Camacho RJ, Ceccherini-Silberstein F, de Luca A, Palmisano L, Paraskevis D, et al. European recommendations for the clinical use of HIV drug resistance testing: 2011 update. *AIDS Rev*. 2011; 13(2):77–108. PMID: [21587341](#).

9. Palmer S, Kearney M, Maldarelli F, Halvas EK, Bixby CJ, Bazmi H, et al. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. *J Clin Microbiol*. 2005; 43(1):406–13. <https://doi.org/10.1128/JCM.43.1.406-413.2005> PMID: 15635002; PubMed Central PMCID: PMCPMC540111.
10. Beerenwinkel N, Gunthard HF, Roth V, Metzner KJ. Challenges and opportunities in estimating viral genetic diversity from next-generation sequencing data. *Front Microbiol*. 2012; 3:329. <https://doi.org/10.3389/fmicb.2012.00329> PMID: 22973268; PubMed Central PMCID: PMCPMC3438994.
11. Trabaud MA, Icard V, Ramiere C, Tardy JC, Scholtes C, Andre P. Comparison of HIV-1 drug-resistance genotyping by ultra-deep sequencing and sanger sequencing using clinical samples. *J Med Virol*. 2017; 89(11):1912–9. <https://doi.org/10.1002/jmv.24872> PMID: 28590068.
12. Parikh UM1 MK, van Zyl G, Mellors JW. Future technologies for monitoring HIV drug resistance and cur. *Curr Opin HIV AIDS* 2017.
13. Moscona R RD, Wax M, Bucris E, Levy I, Mendelson E, Mor O. Comparison between next-generation and Sanger-based sequencing for the detection of transmitted drug-resistance mutations among recently infected HIV-1 patients in Israel, 2000–2014. 2017.
14. Mohamed S, Penaranda G, Gonzalez D, Camus C, Khiri H, Boulme R, et al. Comparison of ultra-deep versus Sanger sequencing detection of minority mutations on the HIV-1 drug resistance interpretations after virological failure. *AIDS*. 2014; 28(9):1315–24. Epub 2014/04/05. <https://doi.org/10.1097/QAD.0000000000000267> PMID: 24698843.
15. Shafer RW. Human Immunodeficiency Virus Type 1 Drug Resistance Mutations Update. *J Infect Dis*. 2017; 216(suppl\_9):S843–S6. <https://doi.org/10.1093/infdis/jix398> PMID: 28968669.
16. Charpentier C, Lee GQ, Rodriguez C, Visseaux B, Storto A, Fagard C, et al. Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response. *J Antimicrob Chemother*. 2015; 70(7):2090–6. <https://doi.org/10.1093/jac/dkv048> PMID: 25755001.
17. Codoner FM, Pou C, Thielen A, Garcia F, Delgado R, Dalmau D, et al. Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects. *PLoS One*. 2011; 6(5): e19461. <https://doi.org/10.1371/journal.pone.0019461> PMID: 21602929; PubMed Central PMCID: PMCPMC3094345.
18. Cozzi-Lepri A, Noguera-Julian M, Di Giallonardo F, Schuurman R, Daumer M, Aitken S, et al. Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing. *J Antimicrob Chemother*. 2015; 70(3):930–40. <https://doi.org/10.1093/jac/dku426> PMID: 25336166; PubMed Central PMCID: PMCPMC4319483.
19. Todesco E, Rodriguez C, Morand-Joubert L, Mercier-Darty M, Desire N, Wirten M, et al. Improved detection of resistance at failure to a tenofovir, emtricitabine and efavirenz regimen by ultradeep sequencing. *J Antimicrob Chemother*. 2015; 70(5):1503–6. <https://doi.org/10.1093/jac/dku557> PMID: 25614045.
20. Vandenhende MA, Bellecave P, Recordon-Pinson P, Reigadas S, Bidet Y, Bruyand M, et al. Prevalence and evolution of low frequency HIV drug resistance mutations detected by ultra deep sequencing in patients experiencing first line antiretroviral therapy failure. *PLoS One*. 2014; 9(1):e86771. <https://doi.org/10.1371/journal.pone.0086771> PMID: 24475178; PubMed Central PMCID: PMCPMC3903565.
21. Johnson JA, Li JF, Wei X, Lipscomb J, Irlbeck D, Craig C, et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy. *PLoS Med*. 2008; 5(7):e158. <https://doi.org/10.1371/journal.pmed.0050158> PMID: 18666824; PubMed Central PMCID: PMCPMC2488194.
22. Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, Kozal MJ, et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. *JAMA*. 2011; 305(13):1327–35. <https://doi.org/10.1001/jama.2011.375> PMID: 21467286; PubMed Central PMCID: PMCPMC3325645.
23. Raymond S, Nicot F, Pallier C, Bellecave P, Maillard A, Trabaud MA, et al. Impact of HIV-1 minority variants on the virus response to a rilpivirine-based first line regimen. *Clin Infect Dis*. 2017. <https://doi.org/10.1093/cid/cix1070> PMID: 29244143.